PICCIN, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 1.818
EU - Europa 449
AS - Asia 292
OC - Oceania 1
Totale 2.560
Nazione #
US - Stati Uniti d'America 1.815
CN - Cina 197
DE - Germania 139
UA - Ucraina 119
GB - Regno Unito 59
TR - Turchia 52
SG - Singapore 37
SE - Svezia 30
IT - Italia 29
FI - Finlandia 28
RU - Federazione Russa 19
BE - Belgio 10
FR - Francia 9
CA - Canada 3
CZ - Repubblica Ceca 2
IE - Irlanda 2
IN - India 2
IR - Iran 2
NL - Olanda 2
AU - Australia 1
BD - Bangladesh 1
KZ - Kazakistan 1
RO - Romania 1
Totale 2.560
Città #
Ashburn 345
Woodbridge 277
Fairfield 164
Jacksonville 139
Chandler 131
Houston 129
Ann Arbor 99
Seattle 69
Wilmington 60
Beijing 54
Cambridge 54
Addison 47
Izmir 44
Nanjing 38
Princeton 27
Singapore 24
Milan 23
Boardman 21
San Diego 21
Shanghai 17
Dearborn 16
Shenyang 15
Kunming 11
Brussels 10
Guangzhou 8
Hebei 8
Jiaxing 8
Nanchang 8
New York 8
Jinan 7
Changsha 6
Norwalk 6
San Mateo 6
Leawood 5
Mountain View 5
Redwood City 5
Des Moines 4
Falls Church 4
Tappahannock 4
Tianjin 4
Washington 4
Hangzhou 3
Monmouth Junction 3
Montréal 3
Munich 3
Ardabil 2
Augusta 2
Dublin 2
Hefei 2
Helsinki 2
Prescot 2
Taizhou 2
Verona 2
Acton 1
Almaty 1
Bremen 1
Brno 1
Changchun 1
Delhi 1
Dhaka 1
Ferrara 1
Formia 1
Jinhua 1
Kilburn 1
Lappeenranta 1
Los Angeles 1
Mcallen 1
Messina 1
Mumbai 1
Ningbo 1
Paris 1
Philadelphia 1
Yellow Springs 1
Zhengzhou 1
Totale 1.984
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 336
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 143
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 139
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 134
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 133
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 117
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 110
null 106
miR-15a and miR-16-1 down-regulation in pituitary adenomas 106
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. 101
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 101
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 100
Antiproliferative effects of somatostatin analogs in pituitary adenomas 86
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 84
Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro 84
SHP-1 restrains cell proliferation in human medullary thyroid carcinoma 83
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 79
Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2 69
Role of complex cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro 68
Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human non-functioning pituitary adenomas in vitro 68
Chemoresistance of Medullary thryroid carcinoma cells is reversed by COX-2 inhibitors in vitro through a PGE2-dependent mechanism 67
Somatostatin inhibits a medullary thyroid carcinoma cell line growth by activating SHP-1 64
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone (GHRH)-secreting bronchial carcinoid 64
SSTR subtypes expression pattern influences the antiproliferative effects of somatostatin and lanreotide on human medullary thyroid carinomas in vitro 56
Somatostatin differentially influences proliferation and gene expression by modulating SHP-1 and cAMP pathways in a human medullary thyroid carcinoma cell line 56
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro 19
Totale 2.573
Categoria #
all - tutte 9.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.431


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020510 76 16 20 61 42 61 43 54 37 54 39 7
2020/2021287 34 29 8 33 12 29 11 32 6 34 49 10
2021/2022330 10 41 31 6 18 12 17 11 10 21 33 120
2022/2023281 28 24 24 35 36 46 24 16 31 1 12 4
2023/2024405 16 28 3 5 12 26 6 273 4 1 0 31
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 2.573